
Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Several years after the onset of the COVID-19 pandemic, labs are still dealing with the effects of missed and delayed screenings
Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines
Test maker Exact Sciences says it expects Cologuard Plus to cut false positives by more than 30 percent
How three companies are addressing screening challenges with tests that help improve chances of early detection